CASE REPORT article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1654048
Case Report: Androgen Receptor-Positive, Locoregionally Advanced Breast Cancer in a Transgender Man and An Update on Breast Cancer Management in a Gender-Diverse Patient Population
Provisionally accepted
Yastira Ramdas1
Trenton Reinicke2Carolyn A Schnurr1Laura Nadeau1Dana Zakalik1Sharon W Lahiri3Andrea Brudvik1Sayee Kiran1Christina M Busuito1
Joshua T Dilworth1*- 1Corewell Health William Beaumont University Hospital, Royal Oak, United States
- 2Oakland University William Beaumont School of Medicine, Rochester, United States
- 3Henry Ford Health System, Detroit, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The role of androgen receptor (AR) signaling in breast cancer is underexplored and may be particularly important in the treatment of patients with higher levels of circulating androgens. We discuss the management of a 70-year-old, postmenopausal transgender man with a six-and-one-half-year history of testosterone therapy, who presented with locoregionally advanced, invasive lobular carcinoma with apocrine features that was estrogen receptor (ER)- negative, progesterone receptor (PR)-negative, human epidermal growth factor receptor 2 (HER2)-positive, and AR-positive. The approach to discontinue his testosterone indefinitely upon diagnosis was determined through shared-decision making with the patient. He received neoadjuvant HER2-directed chemotherapy and achieved a complete metabolic response. He underwent bilateral total mastectomies with left targeted axillary lymph node dissection. Final pathology showed a near complete pathologic response in the breast and a pathologic complete response in three sentinel lymph nodes. He completed a course of conventionally fractionated left chest wall and regional nodal proton beam irradiation and received adjuvant HER-2 directed therapy. He tolerated treatment well and remains disease-free two years since diagnosis. This case report and review underscore the importance of a multi-disciplinary and nuanced approach to personalized management of breast cancer in a gender-diverse patient population. Continued characterization of the AR as a potential therapeutic target in patients with breast cancer is warranted.
Keywords: Male breast cancer, transgender, androgen receptor, Invasive lobular carcinoma, Testosterone therapy, and personalized treatment
Received: 25 Jun 2025; Accepted: 04 Sep 2025.
Copyright: © 2025 Ramdas, Reinicke, Schnurr, Nadeau, Zakalik, Lahiri, Brudvik, Kiran, Busuito and Dilworth. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Joshua T Dilworth, Corewell Health William Beaumont University Hospital, Royal Oak, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.